Cervarix - A Second HPV Vaccine
The FDA has approved a recombinant human papillomavirus (HPV) vaccine (Cervarix – GlaxoSmithKline) for use in girls and women 10-25 years old to prevent infection with HPV types 16 and 18, which have been associated with cervical cancer. A recombinant quadrivalent HPV vaccine (Gardasil – Merck) already on the market in the US prevents infection with HPV types 6, 11, 16 and 18....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Cervarix - A Second HPV Vaccine
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1338
Article Code: 1338a
Date: May 17, 2010
Volume: 52
Page: 37
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1338
Article Code: 1338a
Date: May 17, 2010
Volume: 52
Page: 37
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)